Euticals group lies on 4 companies dealing with the development and production of intermediates and active pharmaceutical ingredients with different production technologies. All the companies belonging to Euticals group have their own product list intended for generics and free markets.It now has a turnover of around €50 million.The group has been acquired in December 2008 byMandarin Capital Partners, the private equity fund specializing in Italian companies seeking to expand in ChinaEuticals AMBROSIA produces the small quantities necessary for the pharmacological development and registration of a new moleculePRO.BIO.SINT. pursues the production of ribonucleic acid and deoxyribonucleic acid derivatives and can produce key intermediates and new sophisticated “antisense” molecules. EUTICALS and PROCHISA evaluate and satisfy exclusive productions.
Products and services